IC
VRNA

Ikarian Capital’s Verona Pharma VRNA Stock Holding History

Ikarian Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-146,831
Closed -$13.9M – 199
2025
Q2 		$13.9M Buy
146,831
+16,831
+13% +$1.25M 2.67% 9
2025
Q1 		$8.25M Buy
130,000
+50,000
+63% +$2.99M 1.02% 17
2024
Q4 		$3.72M Buy
+80,000
New +$3M 0.51% 56
2024
Q3 		– Sell
-201,116
Closed -$2.91M – 173
2024
Q2 		$2.91M Sell
201,116
-174,194
-46% -$2.54M 0.51% 47
2024
Q1 		$6.04M Buy
375,310
+7,842
+2% +$136K 0.66% 48
2023
Q4 		$257K Buy
367,468
+48,877
+15% +$722K 0.02% 123
2023
Q3 		$214K Buy
318,591
+4,914
+2% +$94.6K 0.03% 120
2023
Q2 		$219K Buy
313,677
+85,000
+37% +$1.81M 0.03% 110
2023
Q1 		$4.59M Sell
228,677
-26,454
-10% -$571K 1.04% 33
2022
Q4 		$6.67M Sell
255,131
-60,000
-19% -$799K 1.61% 20
2022
Q3 		$193K Buy
315,131
+15,131
+5% +$128K 0.04% 93
2022
Q2 		$200K Buy
+300,000
New +$1.28M 0.04% 120

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ikarian Capital's VRNA Position: Q3 2025 in Review

Ikarian Capital sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 146,831 shares — an estimated $13.9M sold.

Ikarian Capital first reported a position in VRNA in Q2 2022 and held it in 12 quarters. The position peaked at $13.9M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Ikarian Capital reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 146,831 Verona Pharma shares in Q3 2025, an estimated $13.9M.
  • Ikarian Capital first reported a position in Verona Pharma in Q2 2022 and held it in 12 quarters.
  • Ikarian Capital's Verona Pharma position peaked at $13.9M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.